Few businesses are as competitive and investment-intensive as the pharmaceutical industry. CPLP has developed a specialty in this field, with dozens of cases arising under the Hatch-Waxman Act and many widely known legal successes. With the enormous outlay of resources shouldered by pharmaceutical companies in the course of developing their patent and product portfolios, our client companies are keenly aware of the value CPLP contributes to their bottom line – maximizing IP assets, establishing international patent strategies and vigorously defending charges of infringement. The firm provides world-class litigation services, and approaches all IP matters as potential litigations to be won or avoided. Pharmaceutical companies rely on us to apply this approach in our substantial patent prosecution, licensing, opinion work and counseling practices.

Inter parties rexamination on behalf of Gladerma R&D of Leo Pharmaceutical Products Ltd., US Patent No. 6,753,013 for TACLONEX (August 2008)

“Keep It Candid at the USPTO,” Managing Intellectual Property - International Briefing

“How Seagate has reshaped patent litigation practices,” Managing Intellectual Property

“Protecting Pharmaceutical Products, Processes and R&D from Competitive Challenges,” Pharmaceutical Technology Magazine

“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later;” Part I, Mitteilungen der deutschen Patentanwälte

“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later;” Part II, Mitteilungen der deutschen Patentanwälte

“Recapturing R&D Leadership,” Industry Week